Piers Patten

Editorial: Novel insights into CAR T-cell associated neurotoxicity, volume II

Stella Bouziana, Piers Patten, Thomas Skripuletz, Nora Möhn et autres

The landscape of chimeric antigen receptor (CAR) T-cell therapy continues to evolve at a remarkable pace. Since the first FDA approval in 2017, the therapeutic indications for CAR Tcell products have expanded considerably across haematological neoplasms and beyond malignancies. This rapid application …

gb, de, sk, us (code pays fourni par la source)

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

David J. Allsup, David Allan Cairns, E. Faye Samy, Lelia Duley et autres

Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimens (FLAIR) demonstrated improved progression-free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL). This report presents the secondary end-point of health-related quality of …

gb (code pays fourni par la source)

Functional Intraclonal Heterogeneity in Chronic Lymphocytic Leukemia: Proliferation vs. Quiescence

Daniel J. Friedman, Piers Patten, Robbert Hoogeboom

Chronic lymphocytic leukemia (CLL) is an indolent malignancy with modest proliferation in the lymph nodes and accumulation of quiescent B cells in the peripheral blood. Targeted agents, including BTK inhibitors such as ibrutinib and the BCL2 antagonist venetoclax, have transformed therapy by …

gb (code pays fourni par la source)

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Stephen J. Schuster, Catherine Thieblemont, Michael John Dickinson, Joaquín Martínez‐López et autres

Abstract Background: Tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has been approved in the United States and Europe for adults with r/r FL after ≥2 lines of prior therapy based on the phase 2 ELARA trial (NCT03568461) in 2022. …

us, fr, au, no, jp, nl, es, de, it, gb, be, ch, ie (code pays fourni par la source)

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia

Renata J. Walewska, Toby Andrew Eyre, Adrian John Clifton Bloor, G. Follows et autres

gb (code pays fourni par la source)

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

David John Lewis, Lexy Sorrell, David E. Wright, Annika Pasanen et autres

Background Ibrutinib, a Bruton tyrosine kinase inhibitor, prolongs progression-free survival when added to immunochemotherapy as first line treatment. The ENRICH trial compared the chemotherapy-free combination of ibrutinib and the anti-CD20 antibody rituximab (ibrutinib–rituximab) with standard immunochemotherapy (R-CHOP [rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone] …

gb, se, dk, fi, no (code pays fourni par la source)

MTV ‐guided radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T‐cell therapy

Andrea Kühnl, Stella D. Bouziana, Sally Fiona Barrington, S. Galani et autres

gb (code pays fourni par la source)

Updated Results of RESTART Protocol (RadiothErapy bridging and conSolidaTion for CAR-T) in Large B-cell Lymphoma

George N. Mikhaeel, Stella D. Bouziana, Michael Northend, Christianne Bourlon et autres

gb, us (code pays fourni par la source)

IBCL-1066: ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update

Catherine Thieblemont, Martin H. Dreyling, Michael John Dickinson, Joaquín Martínez‐López et autres

fr, de, au, es, no, us, jp, nl, it, gb, be, ch (code pays fourni par la source)

POSTER: IBCL-1066 ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update

Catherine Thieblemont, Martin H. Dreyling, Michael John Dickinson, Joaquín Martínez‐López et autres

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen et autres

ABSTRACT: With up to 10 years of follow-up, we report results from the final analysis of RESONATE- 2, a phase 3 study of first-line ibrutinib vs chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients aged ≥65 years with …

us, pl, ca, it, gb, be (code pays fourni par la source)

Epcoritamab: the next frontier in the treatment of relapsed/refractory follicular lymphoma

Stella D. Bouziana, Piers Patten